{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:14:54Z","timestamp":1792671294391,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005187","name":"University of Athens","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005187","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Randomized trials have demonstrated that nintedanib is beneficial for Systemic Sclerosis-associated interstitial lung disease (SSc-ILD) with an acceptable safety profile. We evaluated the long-term safety and efficacy of nintedanib in a real-world SSc-ILD cohort. Medical records of SSc patients receiving nintedanib for newly diagnosed fibrotic or progressive ILD between 2020 and 2025 in our center were retrospectively reviewed. Forced vital capacity (FVC%) and diffusing capacity for carbon monoxide (DLCO%), were recorded 12 months before and 12\/24\/36 months after nintedanib initiation and compared by Wilcoxon signed-rank test. Safety analyses included all treated patients; efficacy analyses excluded patients initiating immunosuppression simultaneously with nintedanib. Fifty-one patients (41 female; 34 diffuse SSc; median age and disease duration of 53 and 6 years, respectively) received nintedanib for a median of 33 months (range 4\u201360). Diarrhea was the most frequent adverse event leading to dosage reduction in 31% and permanent discontinuation in 14% of patients, respectively. No additional safety signals emerged in patients receiving mycophenolate (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200918), tocilizumab (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200914), rituximab (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20091), mycophenolate plus tocilizumab (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20095) or mycophenolate plus rituximab (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20092). FVC% and DLCO%, that had declined significantly during the preceding year, remained stable after nintedanib initiation in 23\/35 patients with median FVC changes of +\u20091% and \u2212\u20093% and median DLCO% changes of -2% and \u2212\u20094% after 24 and 36 months, respectively), including patients on reduced dosage. Real-world data show that nintedanib seems to stabilize pulmonary function in progressive SSc-ILD, even at reduced doses, during 3 years of follow-up in about half of patients, without safety concerns when combined with biologic agents.\n                  <\/jats:p>","DOI":"10.1007\/s00296-026-06173-6","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T13:26:04Z","timestamp":1781270764000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Long-term safety and pulmonary function stabilization with nintedanib in systemic sclerosis-associated interstitial lung disease, 2020\u20132025: a real-world retrospective study from a reference centre"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3720-5996","authenticated-orcid":false,"given":"Stylianos","family":"Panopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3102-5708","authenticated-orcid":false,"given":"Vasiliki","family":"Poulia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7878-8078","authenticated-orcid":false,"given":"Nikolaos","family":"Vlachogiannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2162-1362","authenticated-orcid":false,"given":"Vasiliki-Kalliopi","family":"Bournia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2238-0975","authenticated-orcid":false,"given":"Maria G.","family":"Tektonidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5484-2930","authenticated-orcid":false,"given":"Petros P.","family":"Sfikakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"6173_CR1","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","volume":"390","author":"CP Denton","year":"2017","unstructured":"Denton CP, Khanna D (2017) Systemic sclerosis. Lancet (London England) 390:1685\u20131699","journal-title":"Lancet (London England)"},{"key":"6173_CR2","doi-asserted-by":"publisher","first-page":"e001694","DOI":"10.1136\/rmdopen-2021-001694","volume":"7","author":"VK Bournia","year":"2021","unstructured":"Bournia VK, Fragoulis GE, Mitrou P, Mathioudakis K, Tsolakidis A, Konstantonis G et al (2021) All-cause mortality in systemic rheumatic diseases under treatment compared with the general population, 2015\u20132019. RMD Open 7:e001694","journal-title":"RMD Open"},{"key":"6173_CR3","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1136\/ard.2009.114264","volume":"69","author":"AJ Tyndall","year":"2010","unstructured":"Tyndall AJ, Bannert B, Vonk M, Airo P, Cozzi F, Carreira PE et al (2010) Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 69:1809\u20131815","journal-title":"Ann Rheum Dis"},{"key":"6173_CR4","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.autrev.2018.02.008","volume":"17","author":"S Panopoulos","year":"2018","unstructured":"Panopoulos S, Bournia VK, Konstantonis G, Fragiadaki K, Sfikakis PP, Tektonidou MG (2018) Predictors of morbidity and mortality in early systemic sclerosis: Long-term follow-up data from a single-centre inception cohort. Autoimmun Rev 17:816\u2013820","journal-title":"Autoimmun Rev"},{"key":"6173_CR5","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/S2213-2600(19)30480-1","volume":"8","author":"A Perelas","year":"2020","unstructured":"Perelas A, Silver RM, Arrossi AV, Highland KB (2020) Systemic sclerosis-associated interstitial lung disease. Lancet Respir Med 8:304\u2013320","journal-title":"Lancet Respir Med"},{"key":"6173_CR6","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1164\/rccm.200706-877OC","volume":"177","author":"NSL Goh","year":"2008","unstructured":"Goh NSL, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM et al (2008) Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 177:1248\u20131254","journal-title":"Am J Respir Crit Care Med"},{"key":"6173_CR7","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1016\/S2665-9913(19)30144-4","volume":"2","author":"AM Hoffmann-Vold","year":"2020","unstructured":"Hoffmann-Vold AM, Maher TM, Philpot EE, Ashrafzadeh A, Barake R, Barsotti S et al (2020) The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements. Lancet Rheumatol 2:e71\u201383","journal-title":"Lancet Rheumatol"},{"key":"6173_CR8","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/s41584-019-0322-7","volume":"15","author":"JHW Distler","year":"2019","unstructured":"Distler JHW, Gy\u00f6rfi AH, Ramanujam M, Whitfield ML, K\u00f6nigshoff M, Lafyatis R (2019) Shared and distinct mechanisms of fibrosis. Nat Rev Rheumatol 15:705\u2013730","journal-title":"Nat Rev Rheumatol"},{"key":"6173_CR9","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","volume":"370","author":"L Richeldi","year":"2014","unstructured":"Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U et al (2014) Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 370:2071\u20132082","journal-title":"N Engl J Med"},{"key":"6173_CR10","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","volume":"381","author":"KR Flaherty","year":"2019","unstructured":"Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y et al (2019) Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med 381:1718\u20131727","journal-title":"N Engl J Med"},{"key":"6173_CR11","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","volume":"380","author":"O Distler","year":"2019","unstructured":"Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD et al (2019) Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. N Engl J Med 380:2518\u20132528","journal-title":"N Engl J Med"},{"key":"6173_CR12","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1002\/art.38098","volume":"65","author":"F van den Hoogen","year":"2013","unstructured":"van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A et al (2013) 2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology\/European League Against Rheumatism Collaborative Initiative. Arthritis Rheum 65:2737\u20132747","journal-title":"Arthritis Rheum"},{"key":"6173_CR13","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1136\/annrheumdis-2020-217455","volume":"80","author":"AM Hoffmann-Vold","year":"2021","unstructured":"Hoffmann-Vold AM, Allanore Y, Alves M, Brunborg C, Air\u00f3 P, Ananieva LP et al (2021) Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. Ann Rheum Dis 80:219\u2013227","journal-title":"Ann Rheum Dis"},{"key":"6173_CR14","doi-asserted-by":"publisher","first-page":"e002850","DOI":"10.1136\/rmdopen-2022-002850","volume":"9","author":"C Campochiaro","year":"2023","unstructured":"Campochiaro C, De Luca G, Lazzaroni MG, Armentaro G, Spinella A, Vigone B et al (2023) Real-life efficacy and safety of nintedanib in systemic sclerosis-interstitial lung disease: data from an Italian multicentre study. RMD Open 9:e002850","journal-title":"RMD Open"},{"issue":"suppl 67","key":"6173_CR15","first-page":"PA402","volume":"62","author":"V Koether","year":"2023","unstructured":"Koether V, Launay D, Gaubert MR, Pr\u00e9vot G, Mouthon L, Borie R et al (2023) Real-life multicentric national observational study of the use of nintedanib in systemic sclerosis-associated interstitial lung disease. Eur Respir J 62(suppl 67):PA402","journal-title":"Eur Respir J"},{"key":"6173_CR16","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/dvur8b","author":"P Kaenmuang","year":"2026","unstructured":"Kaenmuang P, Goldman NR, Srirangan A, Danzo F, Yip WH, Taki A et al (2026) Nintedanib in systemic sclerosis-associated interstitial lung disease: real-world cohort study on tolerability and discontinuation. Clin Exp Rheumatol. https:\/\/doi.org\/10.55563\/clinexprheumatol\/dvur8b","journal-title":"Clin Exp Rheumatol"},{"key":"6173_CR17","doi-asserted-by":"publisher","first-page":"152891","DOI":"10.1016\/j.semarthrit.2025.152891","volume":"76","author":"K Suzuki","year":"2026","unstructured":"Suzuki K, Akiyama M, Shimanuki K, Fukui H, Kaneko Y (2026) Benefits of nintedanib continuation in systemic autoimmune rheumatic disease-related progressive pulmonary fibrosis: KEIO-SARD-ILD-cohort. Semin Arthritis Rheum 76:152891","journal-title":"Semin Arthritis Rheum"},{"key":"6173_CR18","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1513\/AnnalsATS.202410-1045RL","volume":"22","author":"Y Luo","year":"2025","unstructured":"Luo Y, Assassi S, Mayes MD, Frech TM, Steen VD, Richardson C et al (2025) Use of Nintedanib for the Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease at Expert Scleroderma Centers in the United States. Ann Am Thorac Soc 22:1265\u20131269","journal-title":"Ann Am Thorac Soc"},{"key":"6173_CR19","doi-asserted-by":"publisher","first-page":"370","DOI":"10.31138\/mjr.080825.lfh","volume":"36","author":"A Gkouvi","year":"2025","unstructured":"Gkouvi A, Boutel M, Zioga N, Pagkopoulou E, Mytilinaiou M, Rampiadou C et al (2025) Treatment Response and Safety Profile of Nintedanib in Connective Tissue Disease-Associated Interstitial Lung Disease: A Retrospective Observational Study. Mediterr J Rheumatol 36:370","journal-title":"Mediterr J Rheumatol"},{"key":"6173_CR20","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1007\/s10067-025-07323-0","volume":"44","author":"S M\u0131s\u0131rc\u0131","year":"2025","unstructured":"M\u0131s\u0131rc\u0131 S, Ekin A, Ya\u011f\u0131z B, Co\u015fkun BN, Ba\u015f\u0131b\u00fcy\u00fck F, Birlik AM et al (2025) Treatment with nintedanib is as effective and safe in patients with other connective tissue diseases (CTDs)-interstitial lung disease (ILD) as in patients with systemic sclerosis-ILD: A multicenter retrospective study. Clin Rheumatol 44:1187\u20131195","journal-title":"Clin Rheumatol"},{"key":"6173_CR21","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41584-018-0110-9","volume":"14","author":"E Kravvariti","year":"2018","unstructured":"Kravvariti E, Kitas GD, Mitsikostas DD, Sfikakis PP (2018) Nocebos in rheumatology: emerging concepts and their implications for clinical practice. Nat Rev Rheumatol 14:727\u2013740","journal-title":"Nat Rev Rheumatol"},{"key":"6173_CR22","doi-asserted-by":"publisher","first-page":"2003021","DOI":"10.1183\/13993003.03021-2020","volume":"57","author":"VK Bournia","year":"2021","unstructured":"Bournia VK, Distler O, Kravvariti E, Mitsikostas D, Sfikakis PP (2021) Diarrhoea in systemic sclerosis patients as a nocebo effect of nintedanib. Eur Respir J 57:2003021","journal-title":"Eur Respir J"},{"key":"6173_CR23","first-page":"1221","volume":"13","author":"M Boutel","year":"2023","unstructured":"Boutel M, Boutou A, Pitsiou G, Garyfallos A, Dimitroulas T (2023) Efficacy and Safety of Nintedanib in Patients with Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD): A Real-World Single Center Experience. Diagnostics (Basel Switzerland) 13:1221","journal-title":"Diagnostics (Basel Switzerland)"},{"key":"6173_CR24","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1007\/s00296-024-05695-1","volume":"44","author":"S Panopoulos","year":"2024","unstructured":"Panopoulos S, Tzilas V, Bournia VK, Tektonidou MG, Sfikakis PP (2024) Tocilizumab plus Nintedanib for progressive interstitial lung disease in systemic sclerosis: a one-year observational study. Rheumatol Int 44:1959\u20131966","journal-title":"Rheumatol Int"},{"key":"6173_CR25","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/ard-2024-226430","volume":"84","author":"F Del Galdo","year":"2025","unstructured":"Del Galdo F, Lescoat A, Conaghan PG, Bertoldo E, \u010coli\u0107 J, Santiago T et al (2025) EULAR recommendations for the treatment of systemic sclerosis: 2023 update. Ann Rheum Dis 84:29\u201340","journal-title":"Ann Rheum Dis"},{"key":"6173_CR26","doi-asserted-by":"publisher","first-page":"2500896","DOI":"10.1183\/13993003.02533-2024","volume":"67","author":"KM Antoniou","year":"2026","unstructured":"Antoniou KM, Distler O, Gheorghiu AM, Moor CC, Vikse J, Bizymi N et al (2026) ERS\/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung disease. Eur Respir J 67:2500896","journal-title":"Eur Respir J"},{"key":"6173_CR27","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1136\/annrheumdis-2020-217331","volume":"79","author":"JR Seibold","year":"2020","unstructured":"Seibold JR, Maher TM, Highland KB, Assassi S, Azuma A, Hummers LK et al (2020) Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial. Ann Rheum Dis 79:1478\u20131484","journal-title":"Ann Rheum Dis"},{"key":"6173_CR28","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1080\/03009742.2024.2327159","volume":"53","author":"M Ayano","year":"2024","unstructured":"Ayano M, Tsubouchi K, Suzuki K, Kimoto Y, Arinobu Y, Akashi K et al (2024) Comparing the safety and efficacy of nintedanib starting dose in patients with connective tissue disease-associated interstitial lung diseases. Scand J Rheumatol 53:255\u2013262","journal-title":"Scand J Rheumatol"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-026-06173-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-026-06173-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-026-06173-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T07:17:19Z","timestamp":1784272639000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-026-06173-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":28,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["6173"],"URL":"https:\/\/doi.org\/10.1007\/s00296-026-06173-6","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"12 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the ethics committee of Laikon University Hospital (approval number 267\/26-04-2021) and all patients gave written in formed for their personal data analysis.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"147"}}